Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study

Chang-Chan, D-Y-L; Ríos-Tamayo, Rafael; Rodriguez‐Barranco, Miguel; Redondo‐Sánchez, Daniel; González, Yolanda; Marcos‐Gragera, Rafael; Sánchez, María‐José

doi:10.1007/s12094-020-02541-1

Cited by 23 publications

(23 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MM causes morbidity inducing bone lesions, renal insufficiency, anaemia and infections, among other symptoms 1 . Novel classes of drugs such as proteasome inhibitors (PIs), including bortezomib, ixazomib and carfilzomib, and immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, have made increasing improvements in overall outcomes for MM within the last two decades; however, MM remains largely incurable 2‐5 …”

mentioning

confidence: 99%

“…1 Novel classes of drugs such as proteasome inhibitors (PIs), including bortezomib, ixazomib and carfilzomib, and immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, have made increasing improvements in overall outcomes for MM within the last two decades; however, MM remains largely incurable. [2][3][4][5] Daratumumab (dara), a member of a new class of drugs, namely a human anti-CD38 monoclonal antibody, targets myeloma cells directly and indirectly through the immune system. Dara induces the killing of myeloma cells via different pathways including antibody-dependent cellular cytotoxicity, antibodydependent cellular phagocytosis and complement-dependent cytotoxicity.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database

et al. 2022

View full text Add to dashboard Cite

Daratumumab (dara) has significantly altered the therapeutic landscape of multiple myeloma (MM), especially in the relapsed setting. This study aimed to evaluate the outcomes of dara-containing regimens in the Canadian real-world setting among relapsed and refractory MM available within the national Canadian Myeloma Research Group Database (CMRG-DB). A total of 583 MM patients who received dara-based therapy in second-line or later treatment were included. After a median follow-up of 17.5 months, the median progression-free survival (PFS) and overall survival (OS) for the entire cohort were 13.1 and 32.9 months, respectively. The median PFS and OS were 23.5 and 49.1 months in second-line treatment and decreased to 12.8 and 43.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The annual number of new MM cases in Japan was approximately six per 100,000 in 2018 (17). Although this proportion was nearly the same as those in the United States and Europe (18,19), it has remarkably increased year by year in Japan. In fact, the number of patients with MM in 2018 reached about eight times its number from the 1970s (17).…”

Section: Comparison Of Bone Mineral Density Between Pols and Healthy ...mentioning

confidence: 79%

Mental foramen in panoramic radiography can be a reference for discrimination of punched-out lesions in the mandible in patients with symptomatic multiple myeloma: A cross-sectional study

Shimada

Shiko

Nakamura

et al. 2022

GHM

View full text Add to dashboard Cite

Multiple myeloma (MM) is a hematopoietic malignancy characterized by monoclonal proliferation of plasma cells. MM features bony radiolucencies called punched-out lesions (POLs), which require appropriate diagnosis due to increased risk of surgically-related adverse events. Although dental surgeons can identify dental focal infections (DFIs) in MM patients, the prevalence and characteristics of POLs in the jawbone of MM patients have not been investigated. We examined the prevalence of POLs in the mandible of MM patients, evaluated its relationship with MM International Staging System progression, and examined panoramic radiographs as a diagnostic reference for POLs in a single center in Japan. We identified 98 patients (55 men, 43 women) with a median age of 63 (range, 34 to 91) years. Of these, 18 patients (18.4%) had POLs in the mandible, including two patients in stage I (2/37; 5.4%), six in stage II (6/43; 14.0%), and ten in stage III (10/18; 55.6%). The prevalence of POLs significantly increased with MM stage progression (p < 0.0001). POLs confirmed on computed tomography (CT) were also detected on panoramic radiographs. The Hounsfield unit value at the site of POLs was nearly the same or lower than that of the mental foramen. Although the prevalence of POLs in the mandible is low, dental surgeons need to differentiate POLs as radiological findings when examining DFIs in MM patients. Confirmation of POLs in the mandible is possible by CT and panoramic radiography, and the mental foramen is likely to be a reference for discrimination.

show abstract

“…Meanwhile, the treatment of MM continues to evolve rapidly with the arrival of multiple new drugs and emerging data from randomized trials to guide therapy (4). The 5-year survival rate of young patients with MM has increased from 74.1% in 2010 to 78.5% in 2016 (5). Early diagnosis and timely treatment could considerably improve the survival of patients with MM.…”

Section: Introductionmentioning

confidence: 99%

Secular Trends in the Burden of Multiple Myeloma From 1990 to 2019 and Its Projection Until 2044 in China

Zhao

Niu

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

ObjectiveMultiple myeloma (MM) imposes a heavy burden in China. Understanding the secular trend of MM burden and projecting its future trend could facilitate appropriate public health planning and improve the management of MM.MethodsSex-specific incidence and mortality rates of MM in China from 1990 to 2019 were collected from the Global Burden of Disease 2019 study. The secular trend of MM burden was analyzed by joinpoint regression. Age–period–cohort model was used to analyze the effects of age, period, and birth cohort on MM burden and project future trends up to 2044.ResultsFrom 1990 to 2019, the age-standardized incidence and mortality rates of MM continued to increase in males. For females, the age-standardized rates were stable in MM incidence and decreased in MM mortality. Males had a higher disease burden of MM than females. Age effects were the most significant risk factor for MM incidence and mortality. Moreover, the risk of MM incidence and mortality increased with increasing time period but decreased with birth cohort in males and females. The age-standardized incidence and mortality rates of MM in China is predicted to be continuously increasing over the next 25 years.ConclusionThe burden of MM in China is expected to continue to increase in the future, with significant sex difference. A comprehensive understanding of the risk characteristics and disease pattern of MM could help develop timely intervention measures to effectively reduce its burden.

show abstract

Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study

Cited by 23 publications

References 42 publications

Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database

Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database

Mental foramen in panoramic radiography can be a reference for discrimination of punched-out lesions in the mandible in patients with symptomatic multiple myeloma: A cross-sectional study

Secular Trends in the Burden of Multiple Myeloma From 1990 to 2019 and Its Projection Until 2044 in China

Contact Info

Product

Resources

About